低危乳腺癌术前单次放疗联合延迟手术:SPORT-DS I期试验的肿瘤学结局、毒性与美容效果
SPORT-DS I期前瞻性试验纳入13例65岁及以上、I期单灶luminal A型乳腺癌患者,接受单次20 Gy术前部分乳腺照射后3个月行保乳手术。中位随访48.5个月无复发或癌症相关死亡,84.6%患者出现病理缓解,3年患者自报美容效果良好或优秀者占60%。
要点
- 单次20 Gy术前部分乳腺照射后3个月行保乳手术,11例(84.6%)出现病理缓解,中位残余细胞度1%(范围0-10%)。
- 中位随访48.5个月,无复发或癌症相关死亡记录。
- 3年患者自报美容效果良好或优秀者占60%,仅1例3级伤口感染和1例3级血肿。
核心结论
- 低危乳腺癌保乳手术前单次术前部分乳腺照射可行、耐受性相对良好,并导致高水平的病理缓解。
- 部分乳腺照射后3个月间隔似乎使手术处于放疗后炎症期,进一步延迟部分乳腺照射与手术之间的时间可能改善病理缓解和美容效果。
研究设计与样本
- I期前瞻性试验,纳入65岁及以上、I期单灶luminal A型乳腺癌女性患者。
- 患者接受单次20 Gy部分乳腺照射,3个月后行保乳手术,共治疗13例患者,中位年龄71岁。
- 主要终点为病理缓解率,次要终点为放疗相关毒性和美容效果。
主要发现
- 13例患者中11例(84.6%)出现病理缓解,中位残余细胞度1%(范围0-10%)。
- 中位随访48.5个月,无复发或癌症相关死亡记录。
- 急性放疗相关毒性限于1级皮炎和乳腺疼痛。
- 1年随访时出现1例2级脂肪坏死和2例3级毒性(伤口感染和血肿);2年时仅存1级毒性,但3年随访时出现1例2级毒性(纤维化/硬结)。
- 3年患者自报美容效果良好或优秀者占60%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A novel approach using single-fraction preoperative partial breast irradiation (PBI) for low-risk breast cancer is under study. We sought to investigate the rate of pathologic response (pR), toxicities and cosmetic results related to this new treatment strategy. METHODS: Women of 65 years or older with stage I unifocal luminal A breast cancer were eligible for inclusion in this phase I prospective trial. Patients received a single 20 Gy dose of PBI followed by breast-conserving surgery (BCS) 3 months later. The primary endpoint was the pR rate, and the secondary endpoints were radiation therapy-related toxicity and cosmetic results. RESULTS: Thirteen patients were treated, with a median age of 71. Eleven patients (84.6 %) had pR with a median residual cellularity of 1 % (range: 0-10 %). At median follow-up of 48.5 months, no recurrences or cancer-related deaths were recorded. Acute radiation therapy-related toxicity were limited to grade 1 dermatitis and breast pain. At the 1-year follow-up, there were one grade 2 fat necrosis and two grade 3 toxicities (wound infection and hematoma). Only grade 1 toxicities remained at 2 years, but one grade 2 toxicity (fibrosis/induration) developed by the 3-year follow-up. Three-year patient-reported cosmetic outcomes were good or excellent in 60 % of patients. CONCLUSIONS: Single-fraction preoperative PBI preceding BCS for low-risk breast cancer is feasible, relatively well tolerated and leads to a high level of pR. The 3-month interval after PBI seems to place surgery in a post-radiation inflammatory phase. Further delay between PBI and surgery could improve pR and cosmetic outcome. NCT03917498.
引用
- Lavigne D, Hijal T, Vavassis P, et al. Single preoperative radiation therapy with delayed surgery for low-risk breast cancer: Oncologic outcome, toxicity and cosmesis of the SPORT-DS phase I trial. Radiother Oncol. 2024. PMID: 39218041. doi:10.1016/j.radonc.2024.110515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。